Investors
Infrastructure, not just software — anchored where it can't be copied.
The investment case
A category-defining opportunity, in the one market ready for it.
AGenomics is a rare structural setup: a category-defining opportunity in the one market where the national infrastructure required to build it already exists.
The moat is not the software — a claims-scoring engine is replicable, a pharmacogenomic alert system is replicable. Building both against live UAE HIE infrastructure, UAE payer rule sets, and an Arab-population genomic dataset that exists at scale nowhere else is not something a well-funded competitor can simply purchase.
Revenue scales with the health system's own growth: pricing is against claim volume rather than a large fixed technology cost, and because each deployment replaces nothing, adoption is driven by pilot success and word of mouth between hospital groups rather than a slow, capital-intensive enterprise sales cycle.
The data moat & flywheel
Every hospital that joins deepens the moat.
Each claim processed and each prescribing outcome recorded builds toward the first systematic dataset connecting genomic variants, prescribing decisions, clinical outcomes, and payer-approval patterns specific to Arab and South Asian populations — an asset with standalone commercial value to pharmaceutical companies designing trials or dosing for this region, independent of platform revenue.
Because it compounds through federated updates rather than pooled records, the moat is built by the very mechanism that keeps it PDPL-compliant.
- More hospitals
- More outcomes
- Better federated models
- Stronger clinical & financial performanceMore hospitals
The flywheel and the compliance model are the same architecture.
An Arab-population genomic dataset
Connecting genomic variants, prescribing decisions, clinical outcomes, and payer-approval patterns at a scale that exists nowhere else.
Not purchasable by a competitor
Live UAE HIE access, UAE payer rule sets, and hospital and regulatory trust come only from operating inside the market.
The moat and the compliance model are one
It compounds through federated updates rather than pooled records — the same mechanism that keeps it PDPL-compliant.
Pitch deck
The full deck, available on request.
The full investor pitch deck is available on request under NDA. It covers the market thesis, architecture, regulatory pathway, commercial model, traction, and the roadmap from the current proof-of-concept through hospital pilots to GCC expansion.
Note: the public demo and screenshots on this site use synthetic, fictional data — no real patient information — and are for illustration only.